<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01900002</url>
  </required_header>
  <id_info>
    <org_study_id>2012-0870</org_study_id>
    <secondary_id>NCI-2013-01667</secondary_id>
    <secondary_id>Y-90</secondary_id>
    <secondary_id>2012-0870</secondary_id>
    <secondary_id>P30CA016672</secondary_id>
    <nct_id>NCT01900002</nct_id>
  </id_info>
  <brief_title>Sorafenib Tosylate and Yttrium Y 90 Glass Microspheres in Treating Patients With Liver Cancer That Cannot Be Removed by Surgery</brief_title>
  <official_title>A Phase II Study of Sorafenib and Yttrium-90 Glass Microspheres for Advanced Hepatocellular Carcinoma, BCLC Stage C</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>M.D. Anderson Cancer Center</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Cancer Institute (NCI)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
  </sponsors>
  <source>M.D. Anderson Cancer Center</source>
  <brief_summary>
    <textblock>
      This phase II trial studies how well sorafenib tosylate and yttrium Y 90 glass microspheres&#xD;
      work in treating patients with liver cancer that cannot be removed by surgery. Sorafenib&#xD;
      tosylate may stop the growth of tumor cells by blocking some of the enzymes needed for cell&#xD;
      growth. Yttrium Y 90 glass microspheres use glass beads to carry radiation directly to tumor&#xD;
      cells without harming normal cells. Giving sorafenib tosylate with yttrium Y 90 glass&#xD;
      microspheres may be an effective treatment for liver cancer.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      PRIMARY OBJECTIVES:&#xD;
&#xD;
      I. Median progression-free survival (PFS).&#xD;
&#xD;
      SECONDARY OBJECTIVES:&#xD;
&#xD;
      I. Overall survival (OS). II. Time to radiographic progression (TTRP). III. To evaluate the&#xD;
      safety of the combination of sorafenib (sorafenib tosylate) and Yttrium-90; adverse events&#xD;
      (National Cancer Institute Common Terminology Criteria for Adverse Events version 4.0&#xD;
      [NCI-CTAE v 4.0]).&#xD;
&#xD;
      OTHER OBJECTIVES:&#xD;
&#xD;
      I. Predictive biomarkers of response to therapy and survival: will assess pre-treatment&#xD;
      plasma level of insulin-like growth factor 1 (IGF-1) as above, and assess its predictive&#xD;
      ability of time to progression (TTP) and OS.&#xD;
&#xD;
      OUTLINE:&#xD;
&#xD;
      Patients receive sorafenib tosylate orally (PO) twice daily (BID). After 4 weeks, patients&#xD;
      receive yttrium Y 90 glass microspheres intra-arterially (IA). Courses of sorafenib tosylate&#xD;
      repeat every 4 weeks in the absence of disease progression or unacceptable toxicity.&#xD;
&#xD;
      After completion of study treatment, patients are followed up every 3 months.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">September 13, 2013</start_date>
  <completion_date type="Actual">December 10, 2020</completion_date>
  <primary_completion_date type="Actual">December 10, 2020</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Progression free survival (PFS)</measure>
    <time_frame>From the start of therapy until failure to disease progression or death, assessed up to 4 years</time_frame>
    <description>Will be monitored using the method of Thall et al. Kaplan-Meier method will be used to estimate median progression free survival (PFS) and the 95% confidence interval. Log rank test, univariate and multivariate Cox proportional hazards regression models will be used to identify prognostic factors for progression free survival (PFS).</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Median time to progression (TTP)</measure>
    <time_frame>Up to 4 years</time_frame>
    <description>95% credible interval will be estimated. This will be analyzed using Kaplan-Meier method, Log rank test and Cox proportional hazards regression modeling.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence of adverse events, graded according to National Cancer Institute Common Terminology Criteria for Adverse Events (NCI CTCAE) version 4.0</measure>
    <time_frame>Up to 4 years</time_frame>
    <description>Toxicity rate and mortality rate will be estimated with a 90% credible interval. The posterior probability that the toxicity rate is greater 30% will be evaluated as well.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall response</measure>
    <time_frame>Up to 4 years</time_frame>
    <description>Binary endpoints such as response will be tabulated by frequency and the corresponding 95% confidence interval. Fisher's exact test will be applied to compare the patient characteristics between responders and non-responders. Univariate and multivariate logistic regression models will be fit to identify clinical factors associated with overall response. This will be analyzed using Kaplan-Meier method, Log rank test and Cox proportional hazards regression modeling.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Patient-reported outcomes assessment</measure>
    <time_frame>Up to 4 years</time_frame>
    <description>Discrete or categorical patient-reported outcomes assessments will be tabulated by frequency and 95% confidence interval, while for the continuous data, summary statistics including n, mean, and standard deviation, median, minimum and maximum will be computed.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Quality of life assessments</measure>
    <time_frame>Up to 4 years</time_frame>
    <description>Quality of life assessments will be tabulated by frequency and 95% confidence interval, while for the continuous data, summary statistics including n, mean, and standard deviation, median, minimum and maximum will be computed.</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">40</enrollment>
  <condition>Advanced Adult Hepatocellular Carcinoma</condition>
  <condition>BCLC Stage C Hepatocellular Carcinoma</condition>
  <condition>Recurrent Adult Hepatocellular Carcinoma</condition>
  <condition>Stage III Hepatocellular Carcinoma AJCC v7</condition>
  <condition>Stage IIIA Hepatocellular Carcinoma AJCC v7</condition>
  <condition>Stage IIIB Hepatocellular Carcinoma AJCC v7</condition>
  <condition>Stage IIIC Hepatocellular Carcinoma AJCC v7</condition>
  <condition>Stage IV Hepatocellular Carcinoma AJCC v7</condition>
  <condition>Stage IVA Hepatocellular Carcinoma AJCC v7</condition>
  <condition>Stage IVB Hepatocellular Carcinoma AJCC v7</condition>
  <condition>Unresectable Hepatocellular Carcinoma</condition>
  <arm_group>
    <arm_group_label>Treatment (sorafenib tosylate, TheraSphere)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients receive sorafenib tosylate PO BID. After 4 weeks, patients receive yttrium Y 90 glass microspheres IA. Courses of sorafenib tosylate repeat every 4 weeks in the absence of disease progression or unacceptable toxicity.</description>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Laboratory Biomarker Analysis</intervention_name>
    <description>Correlative studies</description>
    <arm_group_label>Treatment (sorafenib tosylate, TheraSphere)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Quality-of-Life Assessment</intervention_name>
    <description>Ancillary studies</description>
    <arm_group_label>Treatment (sorafenib tosylate, TheraSphere)</arm_group_label>
    <other_name>Quality of Life Assessment</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Sorafenib</intervention_name>
    <description>Given PO</description>
    <arm_group_label>Treatment (sorafenib tosylate, TheraSphere)</arm_group_label>
    <other_name>BAY 43-9006</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Sorafenib Tosylate</intervention_name>
    <description>Given PO</description>
    <arm_group_label>Treatment (sorafenib tosylate, TheraSphere)</arm_group_label>
    <other_name>BAY 43-9006 Tosylate</other_name>
    <other_name>BAY 54-9085</other_name>
    <other_name>Nexavar</other_name>
    <other_name>sorafenib</other_name>
  </intervention>
  <intervention>
    <intervention_type>Radiation</intervention_type>
    <intervention_name>Yttrium Y 90 Glass Microspheres</intervention_name>
    <description>Given IA</description>
    <arm_group_label>Treatment (sorafenib tosylate, TheraSphere)</arm_group_label>
    <other_name>TheraSphere</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Subjects must be able to understand and be willing to sign the written informed&#xD;
             consent form; a signed informed consent form must be appropriately obtained prior to&#xD;
             the conduct of any trial-specific procedure&#xD;
&#xD;
          -  Life expectancy of at least 12 weeks (3 months)&#xD;
&#xD;
          -  Patients with histological or cytologically documented hepatocellular carcinoma (HCC)&#xD;
             (documentation of original biopsy for diagnosis is acceptable if tumor tissue is&#xD;
             unavailable) or clinical diagnosis by American Association for the Study of Liver&#xD;
             Diseases (AASLD) criteria in cirrhotic subjects is required; for subjects without&#xD;
             cirrhosis histological confirmation is mandatory&#xD;
&#xD;
          -  Patients must have at least one tumor lesion that meets the following criteria: the&#xD;
             lesion can be accurately measured in at least one dimension according to Response&#xD;
             Evaluation Criteria in Solid Tumor (RECIST)&#xD;
&#xD;
          -  The target lesion(s) has not been previously treated with local therapy (such as&#xD;
             surgery, radiation therapy, hepatic arterial therapy, chemoembolization,&#xD;
             radiofrequency ablation, percutaneous ethanol injection or cryoablation)&#xD;
&#xD;
          -  Patients who have received local therapy, such as surgery, radiation therapy, hepatic&#xD;
             arterial embolization, chemoembolization, radiofrequency ablation, percutaneous&#xD;
             ethanol injection or cryoablation are eligible if the previously treated lesions have&#xD;
             progressed or recurred can be identified as target lesions; local therapy must have&#xD;
             been completed at least 4 weeks prior to the baseline scan&#xD;
&#xD;
          -  Patients who have received yttrium-90 microspheres are not eligible&#xD;
&#xD;
          -  Patients who have an Eastern Cooperative Oncology Group (ECOG) performance status (PS)&#xD;
             =&lt; 1&#xD;
&#xD;
          -  Patients who are categorized under Barcelona-ClÄ±nic Liver Cancer (BCLC)-C stage&#xD;
&#xD;
          -  Cirrhosis grade of Child-Pugh class A; Child-Pugh status should be calculated based on&#xD;
             clinical findings and laboratory results during the screening period&#xD;
&#xD;
          -  Platelet count &gt;= 60 x 10^9/L&#xD;
&#xD;
          -  Hemoglobin &gt;= 8.5 g/dL&#xD;
&#xD;
          -  Total bilirubin =&lt; 2.5 mg/dl&#xD;
&#xD;
          -  Alanine transaminase (ALT) and aspartate aminotransferase (AST) =&lt; 5 x upper limit of&#xD;
             normal&#xD;
&#xD;
          -  Serum creatinine =&lt; 1.5 x the upper limit of normal&#xD;
&#xD;
          -  Prothrombin time (PT)-international normalized ratio (INR) =&lt; 2.3 or PT =&lt; 6 seconds&#xD;
             above control&#xD;
&#xD;
          -  All acute toxic effects of any prior treatment have resolved to National Cancer&#xD;
             Institute-Common Terminology Criteria for Adverse Events (NCI-CTCAE) v4.0 grade 1 or&#xD;
             less at the time of signing the informed consent form (ICF)&#xD;
&#xD;
          -  Women of childbearing potential must have a negative serum pregnancy test performed&#xD;
             within 7 days prior to the start of study drug; post-menopausal women (defined as no&#xD;
             menses for at least 1 year) and surgically sterilized women are not required to&#xD;
             undergo a pregnancy test&#xD;
&#xD;
          -  Subjects (men and women) of childbearing potential must agree to use adequate&#xD;
             contraception beginning at the signing of the ICF until at least 30 days after the&#xD;
             last dose of study drug; the definition of adequate contraception will be based on the&#xD;
             judgment of the principal investigator or a designated associate&#xD;
&#xD;
          -  Subject must be able to swallow and retain oral medication&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Main portal vein thrombosis (PVT)&#xD;
&#xD;
          -  Patients who are eligible for curative treatment (ablation or resection or&#xD;
             transplantation)&#xD;
&#xD;
          -  Previous or concurrent cancer other than HCC unless without evidence of disease for 5&#xD;
             or more years prior to entry, except cervical cancer in-situ, treated basal cell&#xD;
             carcinoma, or superficial bladder tumor&#xD;
&#xD;
          -  Tumor replacement &gt; 70% of total liver volume based on visual estimation by the&#xD;
             investigator OR tumor replacement &gt; 50% of total liver volume in the presence of&#xD;
             albumin &lt; 3 mg/dL&#xD;
&#xD;
          -  Contraindications to angiography and selective visceral arterial catheterization&#xD;
&#xD;
          -  Any known contraindications to sorafenib including allergic reaction, pill-swallowing&#xD;
             difficulty, uncontrolled hypertension or history of cardiac disease, significant&#xD;
             gastrointestinal (GI) bleed within 30 days, metastatic brain disease, renal failure&#xD;
             requiring dialysis&#xD;
&#xD;
          -  Concomitant treatment or within 28 days of one of the following:&#xD;
&#xD;
               -  Any other systemic anticancer agent other than agents used for cancer prevention&#xD;
&#xD;
               -  Subjects who have used strong cytochrome P450 3A4 (CYP3A4) inducers (e.g.,&#xD;
                  phenytoin, carbamazepine, phenobarbital, St. John's Wort [hypericum perforatum],&#xD;
                  dexamethasone at a dose of greater than 16 mg daily, or rifampin [rifampicin],&#xD;
                  and/or rifabutin) within 28 days before treatment&#xD;
&#xD;
               -  UDP glycosyltransferase 1 family, polypeptide A1 (UGT 1A1) and UDP&#xD;
                  glycosyltransferase 1 family, polypeptide A9 (UGT 1A9) substrates (e.g.,&#xD;
                  irinotecan)&#xD;
&#xD;
               -  P-glycoprotein (Gp) substrates (e.g., Digoxin)&#xD;
&#xD;
          -  Prior radiation therapy to the liver&#xD;
&#xD;
          -  Prior systemic therapy for the treatment of HCC, including sorafenib&#xD;
&#xD;
          -  Any history of symptomatic pulmonary compromise, such as chronic obstructive pulmonary&#xD;
             disease&#xD;
&#xD;
          -  Any prior intervention for, or ongoing compromise of, the ampulla of Vater or&#xD;
             biliary-enteric anastomosis&#xD;
&#xD;
          -  Clinically evident ascites (trace ascites on imaging is acceptable)&#xD;
&#xD;
          -  Pregnant or breast-feeding patients&#xD;
&#xD;
          -  A positive serum pregnancy test within 14 days prior to treatment in women of&#xD;
             childbearing potential&#xD;
&#xD;
          -  Uncontrolled hypertension (systolic pressure &gt; 140 mm Hg or diastolic pressure &gt; 90 mm&#xD;
             Hg [NCI-CTCAE v4.0] on repeated measurement) despite optimal medical management&#xD;
&#xD;
          -  Active or clinically significant cardiac disease including:&#xD;
&#xD;
               -  Congestive heart failure-New York Heart Association (NYHA) &gt; class II&#xD;
&#xD;
               -  Active coronary artery disease&#xD;
&#xD;
               -  Cardiac arrhythmias requiring anti-arrhythmic therapy other than beta blockers or&#xD;
                  digoxin&#xD;
&#xD;
               -  Unstable angina (anginal symptoms at rest), new-onset angina within 3 months&#xD;
                  before treatment, or myocardial infarction within 6 months before treatment&#xD;
&#xD;
          -  Evidence or history of bleeding diathesis or uncontrolled coagulopathy&#xD;
&#xD;
          -  Subject with any pulmonary hemorrhage/bleeding event of NCI-CTCAE v4.0 grade 2 or&#xD;
             higher within 4 weeks before treatment; any other hemorrhage/bleeding event of&#xD;
             NCI-CTCAE v4.0 grade 3 or higher within 4 weeks before treatment&#xD;
&#xD;
          -  Subjects with thrombotic, embolic, venous, or arterial events, such as cerebrovascular&#xD;
             accident (including transient ischemic attacks) within 6 months of informed consent&#xD;
&#xD;
          -  Presence of a non-healing wound, non-healing ulcer, or bone fracture&#xD;
&#xD;
          -  History of organ allograft. (Including corneal transplant)&#xD;
&#xD;
          -  Known or suspected allergy or hypersensitivity to any of the study drugs, study drug&#xD;
             classes, or excipients of the formulations given during the course of this trial&#xD;
&#xD;
          -  Any malabsorption condition&#xD;
&#xD;
          -  Inability to comply with the protocol and/or not willing or not available for&#xD;
             follow-up assessments&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Ahmed O Kaseb</last_name>
    <role>Principal Investigator</role>
    <affiliation>M.D. Anderson Cancer Center</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>M D Anderson Cancer Center</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77030</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <link>
    <url>http://www.mdanderson.org</url>
    <description>University of Texas MD Anderson Cancer Center Website</description>
  </link>
  <verification_date>December 2020</verification_date>
  <study_first_submitted>July 11, 2013</study_first_submitted>
  <study_first_submitted_qc>July 11, 2013</study_first_submitted_qc>
  <study_first_posted type="Estimate">July 16, 2013</study_first_posted>
  <last_update_submitted>December 10, 2020</last_update_submitted>
  <last_update_submitted_qc>December 10, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">December 14, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Carcinoma</mesh_term>
    <mesh_term>Carcinoma, Hepatocellular</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Sorafenib</mesh_term>
  </intervention_browse>
  <pending_results>
    <submitted>November 3, 2021</submitted>
  </pending_results>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

